NCT01885676

Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration.

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Biotechnology Institute IMASD · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

* Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals. * This clinical trial was designed to evaluate the efficacy and safety of using a preparation of autologous plasma rich in growth factors (PRGF-Endoret) in the treatment of androgenetic alopecia.

Conditions

• Androgenetic Alopecia

Interventions

Type	Name	Description
DEVICE	PRGF-Endoret	PRGF-Endoret mesotherapy micro injection.
OTHER	Saline Solution	Saline Solution mesotherapy micro injection

Timeline

• Start date: 2013-09-16
• Primary completion: 2015-09-01
• Completion: 2017-12-18
• First posted: 2013-06-25
• Last updated: 2025-02-06

Locations

2 sites across 1 country: Spain